Miroculus builds the Miro Canvas platform, a compact, cartridge-based system that automates complex protocols such as NGS library preparation. The company positions its technology as a sample-prep automation solution aimed at making next-generation sequencing more accessible to clinical labs. Leadership says proceeds from the new financing will be used to build out the commercial team and expand the company’s Beta program ahead of a full commercial launch this fall. Investors highlighted Miroculus’ digital microfluidics technology and initial lab workflow automation products. The company frames its mission around advancing science and improving patient access to advanced care, particularly in oncology. Miroculus solicits inquiries to join its expanded Beta program via contact@miroculus.com. Miroculus develops low-cost, rapid microRNA profiling diagnostics that detect cancer-associated microRNA in blood or tissue. Its testing panels use biochemistry 'traps' that close when target microRNA are present, producing a green signal. Tests require only one milliliter of blood, deliver results in about 60 minutes, and can be processed with a smartphone or computer. The company plans to focus the next 18 months on clinical validation and is building an open-source diagnostics platform, Miriam, to crowdsource microRNA biomarker data and expand its test panels. Financially, Miroculus has raised the first $2.3M tranche of a planned $3.6M seed round and is seeking the remaining $1.3M over the next 90 days. The startup is based in the Bay Area and positions its offering as an affordable, easy-to-use alternative that avoids full-service laboratory equipment.

Total raised

$2M

Funding rounds

2

Latest round

Seed

Latest activity

Apr 2015